United Therapeutics Corp DEL
UTHRNASDAQStock · Data from SEC EDGAR 13F · Held by 11 of 87 tracked investors
United Therapeutics Corp DEL at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation67
- Growth73
- Profitability95
- Quality85
- Debt100
- Stability100
- ✓Out of 100 USD of revenue, 42 USD is left as net profit.
- ✓It earns 19 USD a year on every 100 USD of invested capital (ROE).
- It has more cash than debt.
Is the stock expensive?
Reasonably pricedFor 1 USD of annual earnings you pay 21.2 USD. Based on next year's estimates 17.3 USD.
- P/E
- 21.2×
- P/S
- 8.0×
- EV/EBITDA
- 15.2×
Is the company growing?
GrowingRevenue over 3 years grew 18.0% a year. Last year -1.9%.
Does it make money?
ExcellentChart UTHR
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
11JS Jim Simons Renaissance Technologies | 1.27% |
RD Ray Dalio Bridgewater Associates | 0.25% |
SC Steven Cohen Point72 Asset Management | 0.12% |
JG Joel Greenblatt Gotham Asset Management | 0.1% |
CA Cliff Asness AQR Capital Management | 0.1% |
IE Israel Englander Millennium Management | 0.08% |
Ns Norský státní fond Norges Bank | 0.04% |
Šn Švýcarská národní banka Swiss National Bank | 0.03% |
KG Ken Griffin Citadel Advisors | 0.02% |
PT Paul Tudor Jones Tudor Investment Corp | 0.01% |
KF Ken Fisher Fisher Investments | 0.01% |
Frequently asked questions
How much is United Therapeutics Corp DEL (UTHR) stock?
United Therapeutics Corp DEL shares trade at $591.20, -0.28% over the last trading day. The price is delayed.
What is the market cap of United Therapeutics Corp DEL?
The market cap of United Therapeutics Corp DEL is about $25.4B and its price-to-earnings ratio (P/E) is 21.2.
Which big investors hold United Therapeutics Corp DEL?
According to the latest 13F filings, 11 of 87 tracked investors hold United Therapeutics Corp DEL, for example Jim Simons, Ray Dalio, Steven Cohen.
When will United Therapeutics Corp DEL report its next results?
The next earnings report of United Therapeutics Corp DEL is expected on 4 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.